[go: up one dir, main page]

DE602004016162D1 - Indol-derivate, die durch einen thiazol ring substoren - Google Patents

Indol-derivate, die durch einen thiazol ring substoren

Info

Publication number
DE602004016162D1
DE602004016162D1 DE602004016162T DE602004016162T DE602004016162D1 DE 602004016162 D1 DE602004016162 D1 DE 602004016162D1 DE 602004016162 T DE602004016162 T DE 602004016162T DE 602004016162 T DE602004016162 T DE 602004016162T DE 602004016162 D1 DE602004016162 D1 DE 602004016162D1
Authority
DE
Germany
Prior art keywords
sup
substores
indol derivatives
thiazol ring
thiazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602004016162T
Other languages
English (en)
Inventor
Jean Ackermann
Johannes Aebi
Alfred Binggeli
Uwe Grether
Georges Hirth
Bernd Kuhn
Hans-Peter Maerki
Markus Meyer
Peter Mohr
Matthew Blake Wright
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of DE602004016162D1 publication Critical patent/DE602004016162D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE602004016162T 2003-07-02 2004-06-25 Indol-derivate, die durch einen thiazol ring substoren Expired - Lifetime DE602004016162D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03014476 2003-07-02
EP04100157 2004-01-20
PCT/EP2004/006924 WO2005005423A1 (en) 2003-07-02 2004-06-25 Indolyl derivatives substituted with a thiazole ring and their use as ppar modulators

Publications (1)

Publication Number Publication Date
DE602004016162D1 true DE602004016162D1 (de) 2008-10-09

Family

ID=33553804

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004016162T Expired - Lifetime DE602004016162D1 (de) 2003-07-02 2004-06-25 Indol-derivate, die durch einen thiazol ring substoren

Country Status (14)

Country Link
US (1) US7235572B2 (de)
EP (1) EP1644368B1 (de)
JP (1) JP4627298B2 (de)
KR (1) KR100796093B1 (de)
CN (1) CN1816550B (de)
AT (1) ATE406369T1 (de)
AU (1) AU2004255580B2 (de)
BR (1) BRPI0412236A (de)
CA (1) CA2530452C (de)
DE (1) DE602004016162D1 (de)
ES (1) ES2313022T3 (de)
MX (1) MXPA06000235A (de)
RU (1) RU2344135C2 (de)
WO (1) WO2005005423A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005060958A1 (en) * 2003-12-19 2005-07-07 Kalypsys, Inc. (5- (2-phenyl)-thiazol-5-ylmethoxy)-indol-1-yl) -acetic acid derivatives and related compounds as modulators of the human ppar-delta receptor for the treatment of metabolic disorders such as type 2 diabetes
KR100989093B1 (ko) 2008-01-18 2010-10-25 한화제약주식회사 생강나무 가지의 추출물을 포함하는 심혈관계 질환의 예방 및 치료용 조성물
US9227969B2 (en) 2013-08-14 2016-01-05 Novartis Ag Compounds and compositions as inhibitors of MEK

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1299176C (en) 1985-07-02 1992-04-21 Guy Dominic Diana Process for preparing isoxazole and furan derivatives
SK280914B6 (sk) * 1994-03-08 2000-09-12 American Home Products Corporation Tiazolidíndiónové deriváty, farmaceutický prostriedok s ich obsahom a ich použitie
GB9604242D0 (en) 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
US6531609B2 (en) 2000-04-14 2003-03-11 Hoffmann-La Roche Inc. Process for the preparation of thiazolidinedione derivatives
GB0024362D0 (en) 2000-10-05 2000-11-22 Glaxo Group Ltd Medicaments
AU2002211901A1 (en) * 2000-10-10 2002-04-22 Smithkline Beecham Corporation Substituted indoles, pharmaceutical compositions containing such indoles and their use as PPAR-gamma binding agents
GB0031107D0 (en) 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
EP1405848B1 (de) * 2001-06-18 2008-05-07 Ono Pharmaceutical Co., Ltd. Tetrahydrochinolinderivatverbindung und die verbindung als wirkstoff enthaltendes arzneimittel
PL369569A1 (en) * 2001-08-29 2005-05-02 Warner-Lambert Company Llc Oral antidiabetic agents
US6867224B2 (en) * 2002-03-07 2005-03-15 Warner-Lambert Company Compounds that modulate PPAR activity and methods of preparation
EP1581521A1 (de) * 2003-01-06 2005-10-05 Eli Lilly And Company Kondensierte heterocyclische verbindungen als ppar modulatoren
BRPI0416238A (pt) * 2003-11-05 2007-01-02 Hoffmann La Roche compostos, processo para a sua preparação, composição farmacêutica que compreende os mesmos, uso dos compostos e métodos para o tratamento e/ou a prevenção de doenças que são moduladas por ppar(delta) e/ou agonistas ppar(alfa)

Also Published As

Publication number Publication date
JP4627298B2 (ja) 2011-02-09
ATE406369T1 (de) 2008-09-15
EP1644368A1 (de) 2006-04-12
AU2004255580B2 (en) 2009-10-08
CA2530452A1 (en) 2005-01-20
BRPI0412236A (pt) 2006-09-12
JP2009501693A (ja) 2009-01-22
CA2530452C (en) 2011-07-26
AU2004255580A1 (en) 2005-01-20
US20050004187A1 (en) 2005-01-06
EP1644368B1 (de) 2008-08-27
ES2313022T3 (es) 2009-03-01
KR100796093B1 (ko) 2008-01-21
WO2005005423A1 (en) 2005-01-20
CN1816550A (zh) 2006-08-09
US7235572B2 (en) 2007-06-26
RU2344135C2 (ru) 2009-01-20
RU2006102866A (ru) 2007-08-20
CN1816550B (zh) 2010-04-28
MXPA06000235A (es) 2006-04-11
KR20060027830A (ko) 2006-03-28

Similar Documents

Publication Publication Date Title
MY138906A (en) Phenyl derivatives as ppar agonists
WO2020227549A8 (en) MODULATORS OF THR-β AND METHODS OF USE THEREOF
MX2020011501A (es) Compuestos novedosos.
AP1635A (en) Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease.
PE20040164A1 (es) Mimeticos de glucocorticoides, procedimientos para su preparacion y composiciones farmaceuticas
UA93872C2 (ru) Дигидротиенопиримидины для лечения воспалительных заболеваний
SE0302760D0 (sv) New compounds
ATE517882T1 (de) Chinolinderivate
NO20045589L (no) Nye forbindelser
EA200301216A1 (ru) Замещенные хинуклидинами мультициклические гетероарилы для лечения заболевания
MX2020012827A (es) Compuestos tetrahidro-1h-pirazino[2,1-a]isoindolilquinolina para el tratamiento de enfermedades autoinmunes.
TW200510317A (en) Caspase inhibitors and uses thereof
TW200612936A (en) Indole derivatives
NO20063275L (no) Anvendelse av substituerte 2-aminotetraliner for forebyggende behandling av Parkinsons sykdom
EA200601194A1 (ru) Новые производные бензофурана, используемые для профилактики или лечения нарушений, связанных с 5-ht-рецептором
MX2008002061A (es) Derivados de tiazolil piperidina utiles como moduladores del receptor h3.
DE602004008959D1 (de) Benzoäbüä1,4üdioxepinderivate
TW200502221A (en) Novel lactams and uses thereof
IL183373A0 (en) 3-[2-(3-acylamino-2-oxo-2h-pyridin-1-yl)-acetylamino]-4-oxo-pentanoic acid derivatives, pharmaceutical compositions containing the same and methods for the preparation thereof
MA30916B1 (fr) Nouveaux derives de benzamide en tant qu'antagonistes de bradykinine
CY1109569T1 (el) Υποκατεστημενα παραγωγα κυκλοεξανο-1,4-διαμινης
WO2007032028A8 (en) Thiazolinones and oxazolinones and their use as ptp1b inhibitors
TW200716547A (en) Piperidin-4-yl-amide derivatives
MX2007011698A (es) Derivados de oxindol sustituido, medicamentos que contienen dichos derivados y uso de los mismos.
WO2006077024A3 (en) 5-aminoindole derivatives

Legal Events

Date Code Title Description
8364 No opposition during term of opposition